Cetyl Tranexamate Mesylate at a Glance
- Derivative of tranexamic acid (TXA)
- Helps even skin tone (dark spots, blemish marks)
- May also visibly reduce redness
- Delivers enhanced penetration/efficacy compared to TXA
Cetyl Tranexamate Mesylate Description
Cetyl tranexamate mesylate is a “next gen” tranexamic acid (TXA) derivative designed to target skin discolorations, including dark spots and post-blemish marks. Though relatively new to the cosmetic scene, early research indicates promising results.
A 2024 comparative study found cetyl tranexamate mesylate penetrates the skin more efficiently than traditional TXA, leading to improved bioavailability and potentially more effective results for evening out skin tone. Although this is encouraging, other suppliers have encapsulated tranexamic acid in various “shells” to improve bioavailability. Until more comparative studies are done, it’s premature to claim that this tranexamic acid derivative is the best form.
In addition to cetyl tranexamate mesylate’s ability to minimize discolorations, manufacturer’s clinical studies also show it can help visibly reduce the appearance of redness when used at a 2% concentration.
Formulators suggest incorporating cetyl tranexamate mesylate into products at a concentration of 1-5%, with a pH range of 3.5-5. A 3% concentration of cetyl tranexamate mesylate is considered equivalent to 1% tranexamic acid.
While the Expert Panel for the Cosmetic Ingredient Review has yet to formally assess cetyl tranexamate mesylate’s safety, our research review did not reveal concerns.
The Personal Care Products Council classifies cetyl tranexamate mesylate as a skin-conditioning agent.
While cetyl tranexamate mesylate is the official INCI name, it’s often marketed under the trade name TXVector.
Cetyl Tranexamate Mesylate References
Personal Care Products Council,accessed December 2024, ePublication
UL Prospector (supplier info), accessed December 2024, ePublication
Journal of Cosmetic Dermatology, November 2024, pages 1-10
Journal of Cosmetic Dermatology, February 2021, pages 561-565